Renal denervation (RDN) is a minimally invasive procedure used to treat hypertension. Owing to the benefits of RDN devices over drug therapy, the market is projected to grow by leaps and bounds.
Europe Holds Dominant Position in Global RDN Devices Market
Geographically, the global RDN devices market is divided into four main regions: North America, Europe, Asia Pacific, and Rest of the World. With an 80% share in 2012, Europe dominated the worldwide market, followed by Asia Pacific. Europe is also the fastest growing regional renal denervation devices market and is estimated to retain its leading position till 2021. There has been a surge in research and development activities in the field of renal denervation in Europe and numerous devices have gained approval over the past few years. The U.K., France, Italy, and Germany are some of the key RDN devices markets in Europe.
North America, Asia Pacific Emerge as Strong Competitors
FDA approvals for renal denervation devices are projected to rise in the next couple of years, boosting the North America RDN devices market. The increasing incidence of cardiovascular diseases owing to poor lifestyle patterns is another factor that has led to the growing demand for renal denervation devices in the region. Asia Pacific also has a widening patient pool, fuelling the RDN devices market in the region.
Medtronic’s Simplicity Most Widely Used RDN Product
Product-wise, the key renal denervation devices are Boston Scientific’s V2 (Vessix Vascular), Medtronic’s Symplicity, St. Jude’s EnlighHTN, ReCor Medical’s Paradise, and Covidien’s OneShot. Presently, only these five devices have received an approval for CE mark certification. However, no RDN therapy has received approval from the U.S. FDA. In 2012, Medtronic’s Symplicity was the most widely used renal denervation device and held an 85.5% share of the overall market. ReCor Medical’s Paradise is the sole ultrasound denervation system that has a CE certification. Thanks to intense competition among these product manufacturers and the threat of new players, innovative technologies are projected to impact the RDN devices market.
Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=400
Radiofrequency-based Renal Denervation Devices Hold Largest Share
There are various technologies used in RDN devices such as ultrasound, radiofrequency, micro-infusion, cryoablation, nano-particles, and radiation. Of these, radiofrequency-based renal denervation devices held the largest share of the overall market owing to their benefits of time efficiency, reproducibility, and safety. This segment is projected to continue its dominance over the RDN devices market through 2021. However, the segment is also forecast to face intense competition from other expanding renal denervation technologies.
RDN Devices Market Stimulated by Rising Incidence of Hypertension
The global renal denervation devices market is primarily driven by the growing incidence of uncontrolled hypertension (uHTN) and treatment resistant hypertension (trHTN). An RDN procedure is short and has a permanent effect on the condition of a patient. As a result, the demand for renal denervation devices has gained momentum. Apart from this, the market is also fuelled by the rapid development of renal denervation devices and rise in the global aging population.
Lack of Awareness among Patients Impeding RDN Market
On one hand, there is a shortage of clinical evidence to support the effect of renal denervation devices, which restricts the expansion of the global market. On the other hand, compared to drug-based therapy, there is scant awareness about renal denervation procedures using RDN devices. This, coupled with unstable reimbursement policies, is projected to hamper the growth of the renal denervation devices market.
Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=400
Renal Denervation Devices Market to Register Outstanding Growth
The global RDN devices market is poised for immense growth till the end of the decade. According to a report by Transparency Market Research, in 2012, the market for renal denervation devices stood at a value of US$88.5 million and is projected to grow to US$1.9 billion by 2021. If this value holds true, the global market will register a CAGR of 41.2% between 2012 and 2021.
Some of the prominent names in the RDN devices market are Boston Scientific Corporation, St. Jude Medical, Kona Medical, Mercator Medsystems, CardioSonic, Medtronic Inc., and Covidien PLC.